LTI 01

Drug Profile

LTI 01

Alternative Names: LTI-01

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lung Therapeutics; University of Texas at Tyler
  • Class Antifibrotics; Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Empyema
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Empyema; Pleural effusion

Most Recent Events

  • 14 Mar 2017 Phase-I clinical trials in Pleural effusion in Australia, New Zealand (Intrapleural) , ACTRN12616001442493p)
  • 14 Mar 2017 Phase-I clinical trials in Empyema in New Zealand, Australia (Intrapleural) (ACTRN12616001442493p)
  • 28 Oct 2014 Preclinical trials in Pleural effusion in USA (unspecified route) (Lung Therapeutics pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top